Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen
in serum from a population of men with prostate-specific antigen
The digital rectal exam, prostate-specific antigen
and transrectal echography in the diagnosis of prostatic cancer.
Clinical utility of measurements of free and total prostate-specific antigen
(PSA): a review.
The second Danish study, also led by Dr Orsted, looked at whether prostate-specific antigen
levels could predict prostate cancer incidence and mortality in the general population.
19,24] Prostate-specific antigen
velocity alone should not be the basis for a decision to biopsy.
Further, prostate-specific antigen
density (PSAD), the ratio of the serum to the size of the prostate calculated as total serum PSA divided by prostate volume has also been correlated as an improvement to total PSA for the prostate can-cer.
(PSA)  had been in clinical use for several years when we encountered a problem with 2 samples that did not give expected results upon dilution.
As part of the Tyrol Prostate-Specific Antigen
Screening Project (J.
Screening for prostate cancer by measuring serum levels of total prostate-specific antigen
(PSA) hits a gray zone when a man's level falls between 2.
respond to "condom effectiveness and prostate-specific antigen
," American Journal of Epidemiology, 2003, 157(4):301-302.
1) In 1979, Wang, et al, purified a protein from prostate tissue, (2) confirmed the identity to the earlier protein and established today's familiar term, prostate-specific antigen
The issuance of these patents join Calydon's collection of patents covering viral therapeutics that target and treat prostate and other cancers which includes United States Patent 5,698,443 and United States Patent 5,871,726 that cover methods for constructing a virus that incorporates the prostate-specific antigen
enhancer gene for use in specifically targeting and killing prostate cancer cells; United States Patent 5,830,686 and United States Patent 5,648,478 that claim a human prostate tissue-specific enhancer gene and methods that utilize the prostate-specific antigen
enhancer gene for treating prostate disease; and United States Patent 5,783,435 that claims methods and compositions for screening therapeutic agents for the treatment of prostate cancer.